康诺亚生物医药科技成都有限公司
CN
 
CN
About Us

荣誉与大事记

  • April 2022

    ● CMG901 for the treatment of gastric 

    cancer and gastroesophageal junction

     adenocarcinoma was granted the 

    Orphan-drug Designation by the FDA.

    ● FDA granted CMG901 Fast Track

     Designation for unresectable or metastatic

     gastric and gastroesophageal junction 

    cancer which have relapsed and/or are 

    refractory to approved therapies.



  • March 2022

    ● Keymed Biosciences was included as eligible 

    stocks of the Shenzhen-Hong Kong Stock Connect.

    ● Keymed Biosciences released positive result from 

    Phase II clinical trial of CM310 at CRSwNP.



  • January 2022

    ● CM350 was approved for clinical trial by NMPA.

    ● The first patient was dosed in clinical trial of CM355 

       a CD20xCD3 bispecificantibody developed by a joint

       venture between Keymed and InnoCare called Tiannuojiancheng 

       Biopharma, for the treatment of CD20+ B-cell malignancies.


  • November 2021

    ● CM338 was approved for clinical trial by NMPA.

    ● CM326 for AD was approved for clinical trial by NMPA.

    ● Keymed entered into an agreement with CSPC in relation to the 

       exclusive licensing and commercialization of the product CM326 

       in the  treatment of moderate to severe asthma, chronic 

       obstructive pulmonary disease (COPD) and other respiratory

       system diseases.

    ● The Phase IIb clinical study of  CM310 recombinant humanized 

       monoclonal antibody injection (CM310AD002) has completed

       the analysis of unblinded data with preliminary statistics,

       showing positive results. 


  • September 2021

    ● CM336 was approved for clinical trials by NMPA.

    ● CM355 was approved for clinical trials by NMPA.


  • July 2021

    ● Keymed Biosciences Inc. was listed on the Main Board 

       of The Stock Exchange of Hong Kong Limited under the stock 

       code “2162”.


  • March 2021

    ● CM326 was approved for clinical trials by NMPA.

    ● CMG901 was approved for clinical trials by FDA.

    ● Keymed entered into an agreement with CSPC in relation to the exclusive licensing and commercialization of the product CM310 in the treatment of moderate to severe asthma, chronic  obstructive pulmonary disease (COPD) and other respiratory 

    system diseases .


  • October-December 2020

    ● CMG901 was approved for clinical trials in October and administered to the first patient in December.

    ● CM313 was approved for clinical trials in November.

    ● Phase IIb clinical trial was initiated in November to evaluate the effect of CM310 in patients with moderate to severe atopicdermatitis, and phase II trial was initiated in December to evaluatethe effect of CM310 in patients with chronic sinusitis with polyps.


  • May-June 2020

    ● In May 2020, CM312 was approved for clinical trials by NMPA.

    ● Phase Ib/IIa clinical trial was initiated in June to evaluate the effect of CM310 in patients with moderate to severe atopic dermatitis.


  • July-September 2019

    ● CM310 was approved for clinical trials in July, and the phase I trial was initiated in September.

  • September 2016

    ● Established in Chengdu as an innovative medicine R&D company.


2022

2021

2020

2019

2016